Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study...
Anchoring the 15th Five-Year Plan: China's High-quality Development is Strengthening Foreign Investors' Confidence
BEIJING, Nov. 7, 2025 /PRNewswire/ -- A news report from China.org.cn on the 8th CIIE and China's high-quality development: Anchoring the 15th Five-Year Plan: China’s High-quality Development is Strengthening Foreign Investors’ Confidence Recently,...